Valuation: Intensity Therapeutics, Inc.

Market Cap 1.02Cr 92.14L 85.22L 76.89L 1.45Cr 96Cr 1.5Cr 10Cr 4.06Cr 51Cr 3.82Cr 3.73Cr 162.56Cr P/E 2026 *
-0.74x
P/E 2027 * -1.35x
Enterprise Value 1.02Cr 92.14L 85.22L 76.89L 1.45Cr 96Cr 1.5Cr 10Cr 4.06Cr 51Cr 3.82Cr 3.73Cr 162.56Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.28%
Yield 2026 *
-
Yield 2027 * -
1 day-1.14%
1 week-3.33%
Current month-10.44%
1 month-9.10%
3 months-26.63%
6 months-33.52%
Current year-70.31%
1 week 2.92
Extreme 2.9201
3.39
1 month 2.8
Extreme 2.8
3.58
Current year 2.8
Extreme 2.8
11.07
1 year 2.8
Extreme 2.8
15
3 years 2.8
Extreme 2.8
286
5 years 2.8
Extreme 2.8
286
10 years 2.8
Extreme 2.8
286
Manager TitleAgeSince
Chief Executive Officer 67 01/04/2012
Director of Finance/CFO 57 11/12/2023
Corporate Officer/Principal - 01/09/2023
Director TitleAgeSince
Chairman 67 01/04/2012
Director/Board Member 60 01/06/2016
Director/Board Member 66 01/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Controller/Auditor

11,000 0.4070%
16/07/26 Free

Chief Executive Officer

78,000 2.8859%
16/07/26 Free

Director

5,500 0.2035%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-3.33%-70.57%-94.20% 1.02Cr
-1.29%-1.76%+51.98%+64.66% 6.63TCr
-0.09%+2.79%+10.75%+95.02% 6.06TCr
+0.63%+1.64%+24.25%+89.70% 5.55TCr
-0.22%-0.33%+10.44%+119.88% 4.76TCr
-0.46%-5.34%+22.13%+28.89% 4.37TCr
-1.95%-15.56%+144.43%+695.29% 3.73TCr
+0.23%+1.66%+14.85%+49.06% 3.66TCr
+2.35%-3.61%+78.64%+60.70% 3.22TCr
+2.01%+6.68%-37.25%+406.79% 2.66TCr
Average +0.03%+0.56%+24.97%+151.58% 4TCr
Weighted average by Cap. -0.03%+0.33%+35.38%+153.72%

Financials

2026 *2027 *
Net sales - -
Net income -1.25Cr -1.13Cr -1.05Cr -94.45L -1.78Cr -117.76Cr -1.84Cr -13Cr -4.99Cr -63Cr -4.69Cr -4.59Cr -199.68Cr -1.55Cr -1.41Cr -1.3Cr -1.17Cr -2.21Cr -146.25Cr -2.29Cr -16Cr -6.19Cr -78Cr -5.82Cr -5.7Cr -247.98Cr
Net Debt - -
Projected Income Statement - Annual - Intensity Therapeutics, Inc.
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
-
Date Price Change Volume
16/26/16 $3.045 -1.14% 2,892
13/26/13 $3.080 -0.65% 25,623
12/26/12 $3.100 -5.49% 11,075
11/26/11 $3.280 +6.15% 6,707
10/26/10 $3.090 -1.90% 8,653
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Intensity Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.080USD
Average target price
18.67USD
Spread / Average Target
+506.06%
  1. Stock Market
  2. Stocks
  3. INTS Stock